EGFR-IN-45 

EGFR-IN-45 is a potent epidermal growth factor receptor (EGFR) pan inhibitor, with IC₅₀s of 0.4 µM and 1.6 µM for EGFR and CDK2, respectively. EGFR-IN-45 also inhibit Topo I and Topo II. EGFR-IN-45 arrests cancer cells in the pre-G1 phase and induces apoptosis^[1].

EGFR-IN-45 (compound 30b) (0-10 μM; 48 hours) exhibits the high anticancer activity against Panc-1, MCF-7, HT-29 and A-549^[1].
EGFR-IN-45 (20 and 100 μM; hours) can inhibit Topo I and Topo II in a dose-dependent manner^[1].
EGFR-IN-45 (0-8 μM; 24 hours) has a high percentage of cell accumulation in the pre-G1 phase in MCF-7^[1].
EGFR-IN-45 (0-8 μM; 24 hours) induces high amounts of apoptosis, with a necrosis percent of 2.99^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

473.53

C₂₈H₂₃N₇O

2765560-03-8

NC1=NC(C2=CC=CC=C2)=NC3=C1C(NC4=CC=CC=C43)=NC5=C(C)N(C)N(C6=CC=CC=C6)C5=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Mekheimer RA, Allam SMR, Al-Sheikh MA, et al. Discovery of new pyrimido[5,4-c]quinolines as potential antiproliferative agents with multitarget actions: Rapid synthesis, docking, and ADME studies. Bioorg Chem. 2022;121:105693.  [Content Brief]